1426 studies found for:    glioma
Show Display Options
Rank Status Study
1 Active, not recruiting A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
Conditions: Newly Diagnosed High-Grade Gliomas;   Diffuse Intrinsic Pontine Glioma
Interventions: Drug: Temozolomide;   Drug: Bevacizumab;   Drug: Irinotecan
2 Recruiting Fluorescence and Glioma Heterogeneity
Condition: Malignant Gliomas
Intervention: Procedure: ALA Test group
3 Recruiting Identification of Clinically Occult Glioma Cells and Characterization of Glioma Behavior Through Machine Learning Analysis of Advanced Imaging Technology
Condition: Glioma
Interventions: Procedure: MRS Imaging;   Procedure: PET Scanning;   Procedure: Diffusion Tensor Imaging
4 Recruiting A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
Conditions: Newly Diagnosed Pediatric Pontine Glioma.;   Newly Diagnosed Pediatric High Grade Glioma.;   Recurrent Pediatric High Grade Glioma.;   Recurrent Pediatric Low Grade Glioma.
Interventions: Biological: HLA-A2 restricted synthetic glioma antigen peptides vaccine;   Drug: Poly ICLC;   Genetic: Reverse transcriptase-polymerase chain reaction;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
5 Recruiting Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma
Conditions: Diffuse Intrinsic Pontine Glioma;   Brainstem Glioma
Intervention:
6 Completed Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma
Conditions: Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma
Interventions: Drug: LS11 (talaporfin sodium);   Device: Light source (interstitial light emitting diodes);   Procedure: Intraoperative placement of device in glioma
7 Unknown  Gene Expression, Immunological Status and Metabolome in Glioma Patients
Condition: Glioma
Interventions: Procedure: Glioma resection;   Other: Blood sampling
8 Terminated Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
Condition: Gliomas
Interventions: Drug: Cilengitide;   Drug: Temozolomide
9 Active, not recruiting PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma
Conditions: Diffuse Intrinsic Pontine Glioma;   Progressive or Refractory High-Grade Glioma
Intervention: Drug: Crenolanib
10 Recruiting Blood Flow MRI for Monitoring Brain Tumors
Condition: Brain Tumors
Intervention:
11 Recruiting Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
Conditions: Diffuse Intrinsic Pontine Glioma;   Anaplastic Astrocytoma;   High Grade Glioma
Interventions: Drug: Lenalidomide;   Radiation: Radiation Therapy
12 Active, not recruiting
Has Results
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
Conditions: Childhood High-grade Cerebral Astrocytoma;   Childhood Oligodendroglioma;   Childhood Spinal Cord Neoplasm;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma
Interventions: Biological: bevacizumab;   Drug: irinotecan hydrochloride;   Radiation: fludeoxyglucose F 18
13 Active, not recruiting Low-Dose Naltrexone for Glioma Patients
Condition: Malignant Glioma
Interventions: Drug: Naltrexone;   Other: Placebo
14 Recruiting An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma
Conditions: Brain Neoplasm;   Glioma
Intervention: Drug: IL13-PE38QQR
15 Recruiting Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Conditions: Diffuse Intrinsic Pontine Glioma;   High-grade Glioma
Intervention: Drug: Chemotherapy
16 Active, not recruiting An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Conditions: Brain Metastases;   Lung Cancer;   Breast Cancer;   Melanoma;   Malignant Glioma
Interventions: Drug: 2B3-101;   Drug: Trastuzumab;   Drug: 2B3-101 60 mg/m2 every 4 weeks;   Drug: 2B3-101 50 mg/m2 every 3 weeks
17 Enrolling by invitation Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
Conditions: Glioma;   Astrocytoma
Interventions: Drug: Temozolomide (for newly diagnosed malignant glioma);   Drug: Temozolomide (for relapsed malignant glioma);   Radiation: Radiotherapy (for patients with newly diagnosed malignant glioma)
18 Active, not recruiting
Has Results
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: Erlotinib hydrochloride
19 Recruiting AZD6244 in Children With Low-Grade Gliomas
Conditions: Optic Glioma;   Pilocytic Astrocytoma;   Low Grade Glioma;   Fibriullary Astrocytoma
Intervention: Drug: AZD6244
20 Enrolling by invitation Permeability Map to Distinguish Progression From Pseudoprogression in High-Grade Glioma
Condition: High Grade Glioma
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years